Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.

Journal:

Cancer Research

Published:

2025-11-17

DOI:

10.1158/0008-5472.can-25-3440

Affiliations:

6

Authors:

23

Go to article

Institutions	Authors	Share
Kronos Bio, Inc., United States of America (USA)	18.000000 18.000000	0.78
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	3.000000	0.13
University of Genova, Italy	1.000000	0.04
Deciphera Pharmaceuticals, Inc., United States of America (USA)	1.000000	0.04

Interested in Oncology and Carcinogenesis?